190 related articles for article (PubMed ID: 37223910)
61. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
Ambrosini G; Do C; Tycko B; Realubit RB; Karan C; Musi E; Carvajal RD; Chua V; Aplin AE; Schwartz GK
Cancer Res; 2019 May; 79(9):2415-2425. PubMed ID: 30885979
[TBL] [Abstract][Full Text] [Related]
62. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.
Shorstova T; Marques M; Su J; Johnston J; Kleinman CL; Hamel N; Huang S; Alaoui-Jamali MA; Foulkes WD; Witcher M
Cancer Res; 2019 May; 79(10):2761-2774. PubMed ID: 30877105
[TBL] [Abstract][Full Text] [Related]
63. The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2019 Apr; 10(4):324. PubMed ID: 30975979
[TBL] [Abstract][Full Text] [Related]
64. MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.
Kim KT; Carroll AP; Mashkani B; Cairns MJ; Small D; Scott RJ
PLoS One; 2012; 7(9):e44546. PubMed ID: 22970245
[TBL] [Abstract][Full Text] [Related]
65. Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R; Velyunskiy M; Dunne SF; Cho BK; Kanojia D; Begg L; Orriols AM; Fleming-Trujillo E; Vadlamani P; Vialichka A; Bolin R; Perrino JN; Roth D; Clutter MR; Zielinski-Mozny NA; Goo YA; Cristofanilli M; Mendillo ML; Vassilopoulos A; Horiuchi D
Cell Chem Biol; 2022 Mar; 29(3):358-372.e5. PubMed ID: 34525344
[TBL] [Abstract][Full Text] [Related]
66. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
Renneville A; Patnaik MM; Chan O; Padron E; Solary E
Leukemia; 2021 Oct; 35(10):2739-2751. PubMed ID: 34175902
[TBL] [Abstract][Full Text] [Related]
67. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
[TBL] [Abstract][Full Text] [Related]
68. Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells.
Sun L; Wu Q; Huan XJ; Tian CQ; Wang YQ; Miao ZH
Mol Cancer Res; 2022 Dec; 20(12):1785-1798. PubMed ID: 36001806
[TBL] [Abstract][Full Text] [Related]
69. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
70. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
71. Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Li Y; Zhao J; Gutgesell LM; Shen Z; Ratia K; Dye K; Dubrovskyi O; Zhao H; Huang F; Tonetti DA; Thatcher GRJ; Xiong R
J Med Chem; 2020 Jul; 63(13):7186-7210. PubMed ID: 32453591
[TBL] [Abstract][Full Text] [Related]
72. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
73. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations.
Ma T; Chen Y; Yi ZG; Li YH; Bai J; Li LJ; Zhang LS
Genes Dis; 2023 Nov; 10(6):2306-2319. PubMed ID: 37554207
[TBL] [Abstract][Full Text] [Related]
74. Achieving clinical success with BET inhibitors as anti-cancer agents.
Shorstova T; Foulkes WD; Witcher M
Br J Cancer; 2021 Apr; 124(9):1478-1490. PubMed ID: 33723398
[TBL] [Abstract][Full Text] [Related]
75. NR5A2 synergizes with NCOA3 to induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis.
Qiao J; Chen Y; Mi Y; Jin H; Huang T; Liu L; Gong L; Wang L; Wang Q; Zou Z
Biochem Biophys Res Commun; 2020 Sep; 530(2):402-409. PubMed ID: 32536370
[TBL] [Abstract][Full Text] [Related]
76. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
77. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
[TBL] [Abstract][Full Text] [Related]
78. BET Inhibition Enhances TNF-Mediated Antitumor Immunity.
Wellinger LC; Hogg SJ; Newman DM; Friess T; Geiss D; Michie J; Ramsbottom KM; Bacac M; Fauti T; Marbach D; Jarassier L; Thienger P; Paehler A; Cluse LA; Kearney CJ; Vervoort SJ; Trapani JA; Oliaro J; Shortt J; Ruefli-Brasse A; Rohle D; Johnstone RW
Cancer Immunol Res; 2022 Jan; 10(1):87-107. PubMed ID: 34782346
[TBL] [Abstract][Full Text] [Related]
79. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells.
Guo L; Li J; Zeng H; Guzman AG; Li T; Lee M; Zhou Y; Goodell MA; Stephan C; Davies PJA; Dawson MA; Sun D; Huang Y
Nat Commun; 2020 Feb; 11(1):740. PubMed ID: 32029739
[TBL] [Abstract][Full Text] [Related]
80. BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.
Markowski MC; De Marzo AM; Antonarakis ES
Expert Opin Investig Drugs; 2017 Dec; 26(12):1391-1397. PubMed ID: 29032717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
